Chris Gayle takes Mangaluru by storm

Bengaluru, Mar 15: All 21 Madhya Pradesh MLAs from Jyotiraditya Scindia's camp, who were lodged here at Prestige Golfshire Club, have been shifted to Ramada hotel in Yelahanka ahead of Monday's floor test in the state assembly.

In view of their arrival, the concerned authorities have strengthened security outside the hotel.

Following the exit of Scindia from Congress, these MLAs claimed to have resigned from the state Legislative Assembly.

On March 11, Congress sent two of its leaders -- Sajjan Singh Verma and Govind Singh -- to Bengaluru in order to pacify some of these rebel MLAs.

Most of the rebel MLAs are perceived close to Scindia and were apparently unhappy at Scindia being "ignored" in the party.
Meanwhile, Madhya Pradesh Congress MLAs, who arrived in Bhopal from Jaipur today morning ahead of the floor test in the Assembly on Monday, have been shifted to Courtyard by Marriott Hotel.

These MLAs were accompanied by senior Congress leader Harish Rawat, who exuded confidence of Kamal-Nath led government winning floor test in the Assembly.

Both Congress and BJP have issued whips to all its MLAs for the legislative assembly session in Madhya Pradesh, which is scheduled to be held from March 16 to April 13.

On Saturday, Madhya Pradesh Governor Lalji Tandon had directed that a floor test will be held in the assembly on Monday.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Bengaluru, Jun 10: The Karnataka government on Wednesday said coronavirus tests conducted in the state has crossed the four lakh mark, while the recovery rate remained at 44 per cent.

Sharing the daily COVID-19 bulletin on his Twitter handle, Medical Education Minister Dr K Sudhakar said till Tuesday 4,00,257 samples were tested in 71 COVID-19 testing labs across the state.

"Karnataka crossed 4 lakh tests mark on Tuesday. So far, we tested 4,00,257 samples in 71 #COVID19 testing labs across the state with a positivity rate of 1.4 per cent," he said.

He tweeted that the state's recovery rate remained healthy at 44 per cent with 2,605 discharges and 5,921 cumulative cases.

The minister said Karnataka was home to nearly a tenth of the total testing labs in India.

According to the Karnataka Health department, out of the four lakh odd samples tested, 3,87,027 samples were reported negative.

The total active cases in the state as on Tuesday evening were 3,248 whereas 66 people lost their lives to coronavirus so far.

Major contributors to the spike in COVID-19 cases in Karnataka are those who returned from Maharashtra recently.